This finding means that the use of clinical anti-inflammatory intervention measures against CRP would potentially benefit the prevention of some diseases such as tongue cancer, bronchitis, hydronephrosis, acute pancreatitis, and bipolar affective disorders but may yield potentially increased risk for some diseases such as colorectal cancer, colon cancer, cerebral ischemia, electrolyte imbalance, PD, encephalitis, epilepsy, degenerative macular diseases, and interstitial lung disease. The gene discussed is CRP; the disease is macular degeneration.